NRG A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian; Fallopian Tube; or Primary Peritoneal Cancer Adult CIRB - Late Phase Emphasis Active Available to Open